RespireRx Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012 - 1988
Net Income	-2.02	-3.87	-4.85	-2.52	-2.59	-4.29	-9.23	-5.96	-2.71	-1.2	Upgrade
Depreciation & Amortization	390,911	552,787	374,080	215,575	8,378	0.01	0.01	0.01	0	0	Upgrade
Share-Based Compensation	687,300	0.06	0.38	779,407	0.03	4.51	4.73	2.71	3.23	0.6	Upgrade
Other Operating Activities	-1,078,209.12	-552,784.15	-374,076.05	-994,979.97	-8,375.86	-0.92	3.16	1.95	-1.41	0.42	Upgrade
Operating Cash Flow	-0.14	-0.96	-0.51	-0.49	-0.43	-0.7	-1.33	-1.3	-0.89	-0.18	Upgrade
Capital Expenditures	0	0	0	0	0	0	0	-0	-0.02	0	Upgrade
Investing Cash Flow	0	0	0	0	0	0	0	-0	-0.02	0	Upgrade
Common Stock Issued	0	0.12	0.16	0	0.2	0.75	0.49	1.19	0.93	0	Upgrade
Other Financing Activities	0.14	0.84	0.33	0.47	0.18	-0.06	0.87	-0.01	0.12	0.04	Upgrade
Financing Cash Flow	0.14	0.96	0.5	0.47	0.38	0.69	1.37	1.19	1.05	0.04	Upgrade
Net Cash Flow	-0	0	-0.02	-0.02	-0.05	-0.01	0.04	-0.11	0.15	-0.14	Upgrade
Free Cash Flow	-0.14	-0.96	-0.51	-0.49	-0.43	-0.7	-1.33	-1.3	-0.9	-0.18	Upgrade
Free Cash Flow Margin	-	-	-	-	-	-	-	-1494.08%	-1466.37%	-	Upgrade
Free Cash Flow Per Share	-0.00	-0.01	-0.02	-1.25	-1.28	-2.88	-7.13	-10.98	-15.25	-4.12	Upgrade

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.